Business context and reporting period
The supplied filing is Helius Medical Technologies, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2019—not a filing for Solana Co. The company develops the PoNS neurostimulation device. PoNS was authorized for use in Canada for a specified balance deficit indication; it did not have U.S., European, or Australian marketing authorization at the reporting date.
Key financial metrics
Amounts are in U.S. dollars; financial statement amounts are in thousands unless stated otherwise.
| Metric | Q2 2019 | Six months ended June 30, 2019 |
|---|---|---|
| Revenue | $518 ($469 product sales; $49 fee revenue) | $1,195 ($1,146 product sales; $49 fee revenue) |
| Gross profit / approximate gross margin | $306 / 59% | $747 / 63% |
| Operating expenses | $6,120 | $13,382 |
| Operating loss | $(5,814) | $(12,635) |
| Net income (loss) | $(186) | $1,138 |
| Operating cash flow | Not separately presented | $(11,214) |
| Cash and working capital | Not separately presented | At June 30: cash $14,311; working capital $11,950, as defined excluding derivative liabilities |
The six-month net income was driven by a $13,837 non-cash gain from changes in fair value of derivative financial instruments; it did not reflect positive operating cash flow. At June 30, total liabilities were $5,415, including $710 of operating lease liabilities and $282 of derivative liabilities. The filing reports no conventional borrowings. Accumulated deficit was $93,854.
Material changes versus the prior comparable period
- Revenue began in 2019: the company reported none in the first half of 2018. Q2 2019 operating loss narrowed to $5,814 from $11,807 in Q2 2018; first-half operating loss narrowed to $12,635 from $16,523.
- First-half operating cash use was broadly similar year over year: $11,214 versus $11,128. Cash fell from $25,583 at December 31, 2018 to $14,311 at June 30, 2019; the prior-year period included $18,400 of offering proceeds.
- Lower R&D and SG&A partly reflected completed product development and much lower stock-based compensation than in 2018. The company also reported higher medical affairs and Canadian commercialization costs.
- Derivative liabilities declined from $13,769 at year-end to $282, producing a large non-cash fair-value gain. This materially affected reported earnings.
Outlook, commentary, risks and unusual items
- Funding and going concern: Management said existing capital resources were expected to fund operations through the end of Q4 2019. The filing states substantial doubt exists about the company’s ability to continue as a going concern; further financing may be needed, with no assurance it will be available on acceptable terms. If funding is insufficient, operations or planned spending could be reduced, or the company could cease operations.
- Regulatory: The FDA denied the company’s de novo request in April 2019, citing insufficient information to distinguish the device’s contribution from physical therapy. The company planned further data collection and a pre-submission meeting to shape a resubmission, but timing and requirements remained uncertain. Applications for Australian authorization and a European CE mark review were ongoing.
- Commercialization: Initial Canadian sales were primarily to self-pay patients through clinics in Montreal and Surrey. The company reported encouraging early patient outcomes and compliance, but these were preliminary company-reported observations. It planned to expand Canadian sales and marketing and develop reimbursement evidence.
- Legal: Two putative shareholder class actions filed in July 2019 allege misleading statements concerning prospects for U.S. FDA authorization. The company said it believed the claims were without merit and intended to defend them; outcomes could not be predicted.
- Other commitments and risks: The company reported approximately $0.5 million in obligations to its device manufacturer for forecast materials. It shared Heuro’s operating costs and losses; maximum stated exposure was CAD$0.4 million. It also had a 4% royalty on certain device and related-service revenue, foreign-exchange exposure that it did not hedge, and lease obligations.
Most important facts for investors to verify
- Confirm the issuer: the supplied text identifies Helius Medical Technologies, Inc. (Nasdaq: HSDT), not Solana Co.
- Check the company’s subsequent cash runway, financing activity, and any updates to its going-concern assessment.
- Verify FDA resubmission plans, required clinical data, regulatory timelines, and decisions in Europe and Australia.
- Assess whether Canadian sales, clinic expansion, reimbursement progress, and patient outcomes support sustainable revenue growth.
- Review developments and potential exposure in the shareholder lawsuits, Heuro arrangement, manufacturing commitments, and derivative warrant liabilities.
- Distinguish operating performance and cash burn from reported net income, which was strongly affected by non-cash derivative remeasurement.